KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Clorox (CLX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Clorox (CLX) over the last 17 years, with Q4 2025 value amounting to $227.0 million.

  • Clorox's Cash & Equivalents fell 2172.41% to $227.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $227.0 million, marking a year-over-year decrease of 2172.41%. This contributed to the annual value of $167.0 million for FY2025, which is 1732.67% down from last year.
  • As of Q4 2025, Clorox's Cash & Equivalents stood at $227.0 million, which was down 2172.41% from $166.0 million recorded in Q3 2025.
  • Clorox's Cash & Equivalents' 5-year high stood at $518.0 million during Q3 2023, with a 5-year trough of $166.0 million in Q3 2025.
  • Its 5-year average for Cash & Equivalents is $267.0 million, with a median of $234.0 million in 2022.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 7558.14% in 2021, then surged by 11130.95% in 2023.
  • Quarter analysis of 5 years shows Clorox's Cash & Equivalents stood at $192.0 million in 2021, then fell by 12.5% to $168.0 million in 2022, then soared by 111.31% to $355.0 million in 2023, then decreased by 18.31% to $290.0 million in 2024, then dropped by 21.72% to $227.0 million in 2025.
  • Its Cash & Equivalents stands at $227.0 million for Q4 2025, versus $166.0 million for Q3 2025 and $167.0 million for Q2 2025.